NEW YORK (GenomeWeb) – Curetis reported today a 9 percent decline in revenues for the first half of 2017, reflecting market volatility for its Unyvero molecular diagnostic system.

For the six-month period ended June 30, Curetis' revenues fell to €594,800 ($695,176) from €654,682 in the first half of 2016. The firm said that due to the uneven spread of early-stage instrument sales throughout the year, revenue volatility is expected quarter to quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.